Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Triulzi, Tiziana"'
Autor:
Rossini A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Giussani M; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Ripamonti F; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Aiello P; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Regondi V; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Balsari A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Dipartimento Di Scienze Biomediche per La Salute, Università Degli Studi Di Milano, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Publikováno v:
Cancer biology & therapy [Cancer Biol Ther] 2020 May 03; Vol. 21 (5), pp. 463-475. Date of Electronic Publication: 2020 Feb 23.
Autor:
Di Cosimo S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Triulzi T; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Pizzamiglio S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., De Cecco L; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., de Azambuja E; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., Fumagalli D; Breast International Group (BIG)-aisbl, Bruxelles, Belgium., Putzai L; Yale Cancer Center, Yale School of Medicine, New Haven, USA., Harbeck N; Brustzentrum der Universität München (LMU), Munchen, Germany., Izquierdo M; Oncology Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland., Peña L; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Daidone MG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Huober J; University of Ulm, Ulm, Germany., Gori S; IRCCS Sacro Cuore-Don Calabria Hospital, Negrar, Verona, Italy., Cinieri S; Antonio Perrino Hospital, Brindisi, Italy., Torri V; IRCCS - Istituto di Ricerche Farmacologiche 'Mario Negri' Milano, Italy., Baselga J; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Piccart M; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., de Braud FG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Apolone G; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Verderio P; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Tagliabue E; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: elda.tagliabue@istitutotumori.mi.it.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Sep; Vol. 118, pp. 1-9. Date of Electronic Publication: 2019 Jul 05.
Autor:
Vernieri C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy. Electronic address: claudio.vernieri@istitutotumori.mi.it., Signorelli D; Unit of Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Galli G; Unit of Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ganzinelli M; Unit of Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Moro M; Tumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Fabbri A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tamborini E; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Marabese M; Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy., Caiola E; Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy., Broggini M; Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy., Hollander L; Laboratory of Methodology for Biomedical Research, Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy., Gallucci R; Unit of Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Vandoni G; Unit of Nutrition Therapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gavazzi C; Unit of Nutrition Therapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Colombo MP; Department of Experimental Oncology and Molecular Medicine, Molecular Immunology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Rizzo AM; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy., Corsetto PA; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy., Pruneri G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; School of Medicine, University of Milan, Milan, Italy., de Braud F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Oncology and Haemato-Oncology Department, University of Milan, Milan, Italy., Sozzi G; Tumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Torri V; Laboratory of Methodology for Biomedical Research, Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy., Garassino MC; Unit of Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: marina.garassino@istitutotumori.mi.it.
Publikováno v:
Clinical lung cancer [Clin Lung Cancer] 2019 May; Vol. 20 (3), pp. e413-e417. Date of Electronic Publication: 2018 Dec 19.
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Autor:
Di Modica M; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sfondrini L; Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy., Regondi V; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Varchetta S; Department of Infectious Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy., Oliviero B; Department of Infectious Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy., Mariani G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bianchi GV; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Generali D; Dipartimento di Terapia Molecolare e Farmacogenomica, Istituti Ospitalieri di Cremona, Cremona, Italy., Balsari A; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Oncotarget [Oncotarget] 2016 Jan 05; Vol. 7 (1), pp. 255-65.
Autor:
Anna Ianza, Tiziana Triulzi, Eva Ciruelos, Manuela Milani, Alfredo Molteni, Fabiola Giudici, Maria Rosaria Cappelletti, Silvia Paola Corona, Francesco Schettini, Carla Strina, Navid Sobhani, Guy Jerusalem, Sherine Loi, Stephen B. Fox, Daniele Generali, Ottavia Bernocchi, Maria Chiara Lazzari, Marianna Sirico
Publikováno v:
Breast Cancer Research and Treatment
Purpose mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19e00b9b8ddae4330d6b3c438c58eedc
https://link.springer.com/article/10.1007/s10549-020-05856-3
https://link.springer.com/article/10.1007/s10549-020-05856-3
Autor:
Daniele Generali, Tiziana Triulzi, Giulia Bianchi, Gabriella Mariani, Andrea Balsari, Viola Regondi, Elda Tagliabue, Barbara Oliviero, Martina Di Modica, Stefania Varchetta, Lucia Sfondrini
Publikováno v:
Scopus-Elsevier
Oncotarget
Oncotarget
Recent clinical data indicate a synergistic therapeutic effect between trastuzumab and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC) patients. In HER2+ BC experimental models and patients, we investigated whether this synergy depe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c43dc35ae941efe5eae0d489f8df08b1
http://www.scopus.com/inward/record.url?eid=2-s2.0-84995511494&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-84995511494&partnerID=MN8TOARS